Skip to Content

Revvity Inc

RVTY: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$224.00RztkswvHljjngqsy

Revvity Earnings: 2023 Outlook Cut Mildly on Life Sciences Uncertainty, China Diagnostics Weakness

Narrow-moat Revvity (formerly known as PerkinElmer) reported weak first-quarter results that were about as expected but trimmed its guidance for the full year, which appears to be pushing down shares in early trading. At first glance, our bottom-line assumptions remain within management's new guidance range, and we do not anticipate changing our $162 fair value estimate based on this announcement. The shares still appear moderately undervalued to us.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of RVTY so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center